Cancer-Associated Myeloid Regulatory Cells
Open Access
- 29 March 2016
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 7, 113
- https://doi.org/10.3389/fimmu.2016.00113
Abstract
Myeloid cells are critically involved in the pathophysiology of cancers. In the tumor microenvironment (TME), they comprise tumor-associated macrophages (TAMs), neutrophils (TANs), dendritic cells and myeloid-derived suppressors cells, which are further subdivided in a monocytic and granulocytic subset. Some of these myeloid cells, in particular TAMs and TANs, are divided into type 1 or type 2 cells, according to the paradigm of T helper type 1 or type 2 cells. Type 1 activated cells are generally characterized as cells that aid tumor rejection, while all other myeloid cells are shown to favor tumor progression. Moreover these cells are often at the basis of resistance to various therapies. Much research has been devoted to study the biology of myeloid cells. This endeavor has proven to be challenging, as the markers used to categorize myeloid cells in the TME are not restricted to particular subsets. Also from a functional and metabolic point of view myeloid cells share many features. Finally, myeloid cells are endowed with a certain level of plasticity, which further complicates studying them outside their environment. In this article, we challenge the exclusive use of cell markers to unambiguously identify myeloid cell subsets in the TME. We further propose to divide myeloid cells according to their pro- or antitumor function into myeloid regulatory or stimulatory cells, as we contend that for therapeutic purposes it is not targeting of cell subsets but rather targeting their protumor traits and therefore myeloid regulatory cells that will push antitumor immunotherapy to the next level.Keywords
Funding Information
- Vlaamse Liga Tegen Kanker
- Vrije Universiteit Brussel
This publication has 113 references indexed in Scilit:
- Cyclooxygenase-2 Inhibition Blocks M2 Macrophage Differentiation and Suppresses Metastasis in Murine Breast Cancer ModelPLOS ONE, 2013
- Tumor-Derived Granulocyte-Macrophage Colony-Stimulating Factor Regulates Myeloid Inflammation and T Cell Immunity in Pancreatic CancerCancer Cell, 2012
- Differential macrophage programming in the tumor microenvironmentTrends in Immunology, 2012
- Origin and Functions of Tumor-Associated Myeloid Cells (TAMCs)Cancer Microenvironment, 2011
- Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and functionTrends in Immunology, 2010
- Immunity, Inflammation, and CancerCell, 2010
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Stromal cell‐derived CSF‐1 blockade prolongs xenograft survival of CSF‐1‐negative neuroblastomaInternational Journal of Cancer, 2009
- Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrowNature Immunology, 2007
- Tumor immunoediting and immunosculpting pathways to cancer progressionSeminars in Cancer Biology, 2007